PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35453376-0	2022	Indapamide Increases IRS1 Expression and Modifies Adiponectin/NLRP3/PPARgamma Crosstalk in Type 2 Diabetic Rats.	Indapamide	0-10	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	50-61	
35453376-1	2022	The current study aimed to evaluate the anti-diabetic effects of canagliflozin (CANA) and indapamide (INDA) and their impacts as adiponectin modulators in experimentally induced type 2 diabetes mellitus (T2DM).	Indapamide	90-100	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	129-140	
35453376-1	2022	The current study aimed to evaluate the anti-diabetic effects of canagliflozin (CANA) and indapamide (INDA) and their impacts as adiponectin modulators in experimentally induced type 2 diabetes mellitus (T2DM).	Indapamide	102-106	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	129-140	
35453376-6	2022	CANA and INDA treatments markedly reduced blood glucose levels, increased adiponectin and insulin secretion, enhanced anti-oxidant defenses, and reduced oxidative burden, with marked anti-inflammatory impact.	Indapamide	9-13	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	74-85	
35453376-10	2022	INDA increased IRS1 expression and modified adiponectin/NLRP3/PPARgamma crosstalk.	Indapamide	0-4	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	44-55